CA3013520C - Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof - Google Patents

Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof Download PDF

Info

Publication number
CA3013520C
CA3013520C CA3013520A CA3013520A CA3013520C CA 3013520 C CA3013520 C CA 3013520C CA 3013520 A CA3013520 A CA 3013520A CA 3013520 A CA3013520 A CA 3013520A CA 3013520 C CA3013520 C CA 3013520C
Authority
CA
Canada
Prior art keywords
compound
formula
acid
process according
sodium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3013520A
Other languages
English (en)
French (fr)
Other versions
CA3013520A1 (en
Inventor
Zhaozhong DING
Fei Sun
Yinghu HU
Yilong ZHOU
Rui Zhao
Ling Yang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CA3013520A1 publication Critical patent/CA3013520A1/en
Application granted granted Critical
Publication of CA3013520C publication Critical patent/CA3013520C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CA3013520A 2016-02-05 2017-02-04 Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof Active CA3013520C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610082028.3 2016-02-05
CN201610082028.3A CN107043378A (zh) 2016-02-05 2016-02-05 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
PCT/CN2017/072893 WO2017133686A1 (zh) 2016-02-05 2017-02-04 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体

Publications (2)

Publication Number Publication Date
CA3013520A1 CA3013520A1 (en) 2017-08-10
CA3013520C true CA3013520C (en) 2022-07-19

Family

ID=59500148

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3013520A Active CA3013520C (en) 2016-02-05 2017-02-04 Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof

Country Status (28)

Country Link
US (2) US10654856B2 (cg-RX-API-DMAC10.html)
EP (1) EP3412673B1 (cg-RX-API-DMAC10.html)
JP (1) JP6877449B2 (cg-RX-API-DMAC10.html)
KR (1) KR102371500B1 (cg-RX-API-DMAC10.html)
CN (2) CN107043378A (cg-RX-API-DMAC10.html)
AR (1) AR107549A1 (cg-RX-API-DMAC10.html)
AU (1) AU2017214134B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018015879B1 (cg-RX-API-DMAC10.html)
CA (1) CA3013520C (cg-RX-API-DMAC10.html)
CL (1) CL2018002094A1 (cg-RX-API-DMAC10.html)
DK (1) DK3412673T3 (cg-RX-API-DMAC10.html)
EA (1) EA034581B1 (cg-RX-API-DMAC10.html)
ES (1) ES2852323T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20210103T1 (cg-RX-API-DMAC10.html)
HU (1) HUE053455T2 (cg-RX-API-DMAC10.html)
IL (1) IL260999B (cg-RX-API-DMAC10.html)
LT (1) LT3412673T (cg-RX-API-DMAC10.html)
MX (1) MX374298B (cg-RX-API-DMAC10.html)
MY (1) MY190551A (cg-RX-API-DMAC10.html)
NZ (1) NZ744885A (cg-RX-API-DMAC10.html)
PH (1) PH12018501642A1 (cg-RX-API-DMAC10.html)
PL (1) PL3412673T3 (cg-RX-API-DMAC10.html)
PT (1) PT3412673T (cg-RX-API-DMAC10.html)
SG (1) SG11201806685VA (cg-RX-API-DMAC10.html)
SI (1) SI3412673T1 (cg-RX-API-DMAC10.html)
TW (1) TW201728590A (cg-RX-API-DMAC10.html)
UA (1) UA124100C2 (cg-RX-API-DMAC10.html)
WO (1) WO2017133686A1 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9815850B2 (en) 2016-02-05 2017-11-14 Denali Therapeutics Inc. Compounds, compositions and methods
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
BR112021015577A2 (pt) 2019-02-08 2021-10-05 Research & Business Foundation Sungkyunkwan University Complexo-colesterol agonista do receptor toll-like 7 ou 8 e uso do mesmo
CN115666637A (zh) 2020-03-02 2023-01-31 蛋白科技先锋 基于病原体细胞壁骨架的模拟活病原体的纳米粒子及其制备方法
EP4194008A4 (en) 2020-08-04 2025-01-08 Progeneer Inc. Kinetically acting adjuvant ensemble
WO2022031021A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적 제어가 가능한 아주번트를 포함하는 mrna 백신
US20230277525A1 (en) 2020-08-04 2023-09-07 Progeneer Inc Conjugate of functional drug and toll-like receptor 7 or 8 agonist of which active site is temporarily inactivated and use thereof
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
WO2025110816A1 (ko) 2023-11-23 2025-05-30 프로지니어 주식회사 암의 치료를 위한 활성화 부위가 일시적으로 비활성화된 톨-유사 수용체 7 또는 8 작용자와 항암 치료의 병용요법

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082247A1 (en) 2007-12-21 2009-07-02 Industrial Research Limited Process for preparing immucillins having a methylene link
UY32306A (es) 2008-12-09 2010-07-30 Gilead Sciences Inc Derivados de pteridinona y pirimidinodiazepinona y composiciones farmacéuticas que modulan en forma selectiva los receptores tipo toll, métodos y usos
MX386924B (es) * 2012-10-10 2025-03-19 Janssen Sciences Ireland Uc Derivados pirrolo[3,2-d]pirimidínicos para el tratamiento de infecciones víricas y otras enfermedades.
JP6216387B2 (ja) * 2012-11-20 2017-10-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 新規化合物
SMT201700378T1 (it) * 2012-11-20 2017-09-07 Glaxosmithkline Llc Nuovi composti
WO2015168269A1 (en) * 2014-05-01 2015-11-05 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
CN112898308B (zh) 2014-08-15 2026-08-07 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
CN105367576A (zh) 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
KR102112192B1 (ko) * 2015-11-05 2020-05-19 치아타이 티안큉 파마수티컬 그룹 주식회사 Tlr7 효능제로서의 7-(티아졸-5-일)피롤로피리미딘 화합물
CN107043377A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043379A (zh) 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的晶型a、其制备方法和医药用途

Also Published As

Publication number Publication date
EP3412673B1 (en) 2020-11-25
HK1259183A1 (zh) 2019-11-29
LT3412673T (lt) 2021-03-10
IL260999B (en) 2021-02-28
BR112018015879B1 (pt) 2024-02-15
CN108602832B (zh) 2020-10-09
HUE053455T2 (hu) 2021-06-28
US10654856B2 (en) 2020-05-19
CA3013520A1 (en) 2017-08-10
HRP20210103T1 (hr) 2021-03-05
WO2017133686A1 (zh) 2017-08-10
JP6877449B2 (ja) 2021-05-26
PH12018501642B1 (en) 2019-06-03
CN107043378A (zh) 2017-08-15
KR102371500B1 (ko) 2022-03-07
AU2017214134B2 (en) 2020-08-27
PL3412673T3 (pl) 2021-07-26
UA124100C2 (uk) 2021-07-21
KR20180104724A (ko) 2018-09-21
EP3412673A4 (en) 2019-07-03
EP3412673A1 (en) 2018-12-12
BR112018015879A2 (pt) 2018-12-26
PH12018501642A1 (en) 2019-06-03
EA201891769A1 (ru) 2019-04-30
AU2017214134A1 (en) 2018-08-23
PT3412673T (pt) 2021-02-15
AR107549A1 (es) 2018-05-09
ES2852323T3 (es) 2021-09-13
SG11201806685VA (en) 2018-09-27
US20190040072A1 (en) 2019-02-07
MY190551A (en) 2022-04-27
JP2019505531A (ja) 2019-02-28
CL2018002094A1 (es) 2018-12-07
US20200239484A1 (en) 2020-07-30
SI3412673T1 (sl) 2021-04-30
MX2018009502A (es) 2018-12-11
EA034581B1 (ru) 2020-02-21
MX374298B (es) 2025-03-06
NZ744885A (en) 2022-07-01
TW201728590A (zh) 2017-08-16
CN108602832A (zh) 2018-09-28
DK3412673T3 (da) 2021-01-18

Similar Documents

Publication Publication Date Title
AU2017214134B2 (en) Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof
CA3013518C (en) Tlr7 agonist crystalline form a, preparation method and use thereof
AU2017214135B2 (en) TLR7 agonist trifluoroacetate salt and crystalline form B thereof, preparation methods and uses
CA3013682C (en) Maleate salt of a pyrrolo[3,2-d]pyrimidine compound as tlr7 agonist and crystalline forms c, d and e thereof
CZ20032654A3 (cs) Způsob výroby 4,6-diaminopyrimido(5,4-d)pyrimidinů
JPS634544B2 (cg-RX-API-DMAC10.html)
CN102438994B (zh) 制备嘧啶衍生物的方法
HK1259183B (en) Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof
Jiang et al. Design, synthesis and cytotoxicity of novel 2-arylvinyl-4-aminoquinoline derivatives
HK1259182B (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200225

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241205

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241205

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241205

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251202

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251202